menu
    • menu

    Company profile for Privo Technologies

    NEW Drugs in Dev: 1
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Privo Technologies is a privately funded, Phase III oncology company that spun out of the world-renowned Langer Laboratory at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts, USA. Privo is developing a novel, nanotechnology-based drug delivery platform capable of local and systemic delivery of a constant, controlled therapeutic dose through the mucosa. This approach eliminates needles, avoids stomac...
    Privo Technologies is a privately funded, Phase III oncology company that spun out of the world-renowned Langer Laboratory at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts, USA. Privo is developing a novel, nanotechnology-based drug delivery platform capable of local and systemic delivery of a constant, controlled therapeutic dose through the mucosa. This approach eliminates needles, avoids stomach acids, can significantly reduce toxic side effects of drugs and allows for higher dosing where the drugs can be most effective – all of which improve patient outcomes and compliance.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Privo TechnologiesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Corporate Pl #6b, Peabody, MA 01960
    Telephone
    Telephone
    978-587-2322
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.privotechnologies.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/privo-technologies/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Paris Packaging Week

    Paris Packaging Week

    Not Confirmed

    envelop Contact Supplier

    Paris Packaging Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Privo Technologies Acquires Medico Pharma In Strategic Move
    Privo Technologies Acquires Medico Pharma In Strategic Move

    23 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/privo-technologies-announces-milestone-in-prv211-arm-of-cln-004-clinical-trial-primary-endpoint-met-no-serious-adverse-events-reported-302668552.html

    PR NEWSWIRE
    23 Jan 2026
    Share Share
    Privo Begins Dosing PRV-131 in Arm 3 of CLN-004 Oral Cancer Trial
    Privo Begins Dosing PRV-131 in Arm 3 of CLN-004 Oral Cancer Trial

    10 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/privo-technologies-begins-dosing-prv131-in-arm-3-of-clinical-study-cln-004-a-first-in-class-cisplatin-intratumoral-injectable-targeting-oral-cavity-cancer-302638426.html

    PR NEWSWIRE
    10 Dec 2025
    Share Share
    PRV111, Meets Primary Efficacy Endpoint In Phase 2/3 Trial
    PRV111, Meets Primary Efficacy Endpoint In Phase 2/3 Trial

    17 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/prv111-in-development-as-the-first-non-surgical-therapy-for-early-stage-non-invasive-oral-cancer-and-high-grade-dysplasias-meets-its-primary-efficacy-endpoint-in-ongoing-phase-23-trial-302616269.html

    PR NEWSWIRE
    17 Nov 2025
    Share Share
    Privo Technologies Wraps Phase 2 Run-In In PRV111 Oral Cancer
    Privo Technologies Wraps Phase 2 Run-In In PRV111 Oral Cancer

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/privo-technologies-completes-phase-2-run-in-in-prv111-oral-cancer-trial-highlighting-potential-to-spare-patients-from-surgery-302583764.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    Privo Technologies Launches BeneVet Oncology: Advancing Comp
    Privo Technologies Launches BeneVet Oncology: Advancing Comp

    24 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/privo-technologies-inc-announces-the-launch-of-benevet-oncology-advancing-companion-animal-health-through-innovation-302408525.html

    PR NEWSWIRE
    24 Mar 2025
    Share Share
    Privo Appoints Dr. Albert Collinson as Independent Non-Executive Director
    Privo Appoints Dr. Albert Collinson as Independent Non-Executive Director

    09 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/privo-technologies-inc-appoints-dr-albert-collinson-as-independent-non-executive-director-301982483.html

    PR NEWSWIRE
    09 Nov 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search